株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

シラカバ花粉症:パイプライン分析

Birch Pollen Allergy - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 200930
出版日 ページ情報 英文 40 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.80円で換算しております。
Back to Top
シラカバ花粉症:パイプライン分析 Birch Pollen Allergy - Pipeline Review, H2 2017
出版日: 2017年07月18日 ページ情報: 英文 40 Pages
概要

シラカバ花粉アレルギーはシラカバの花粉によって生じる花粉症の一種で、春に原因不明の目・鼻の症状を引き起こします。シラカバ花粉による鼻アレルギーの症状には、風邪やインフルエンザに類似した症状(発熱を伴わないもの)、くしゃみ、喘鳴や呼吸不足による呼吸障害、鼻づまり、結膜炎などが含まれています。通常、抗ヒスタミン剤や非鎮静型抗ヒスタミン剤、アレルギー抑制薬、コルチコステロイド、鼻充血抑制剤などが治療薬として処方されています。

当レポートでは、世界各国での白樺花粉症の治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

イントロダクション

  • 分析範囲

シラカバ花粉症の概要

治療薬の開発

  • シラカバ花粉アレルギー向けパイプライン製品:概要
  • シラカバ花粉アレルギー向けパイプライン製品:比較分析

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • ALK-Abello A/S
  • Allergopharma Joachim Ganzer KG
  • Anergis SA
  • Biomay AG
  • Circassia Pharmaceuticals Plc
  • HAL Allergy BV
  • Stallergenes S.A.

治療薬の評価

  • 単剤製品
  • 標的別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis
  • Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis
  • AllerT
  • Birch-SPIRE
  • BM-31
  • PL-102
  • rBet v1
  • rBet v1-FV
  • STG-210

最新パイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9542IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Birch Pollen Allergy - Pipeline Review, H2 2017, provides an overview of the Birch Pollen Allergy (Immunology) pipeline landscape.

Birch pollen allergy is a reaction which occurs soon after exposure to pollen of birch trees. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies. Treatment includes drugs belonging to class of antihistamines.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Birch Pollen Allergy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Birch Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Birch Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 2, 1 and 1 respectively.

Birch Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Birch Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Birch Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Birch Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Birch Pollen Allergy (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Birch Pollen Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Birch Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Birch Pollen Allergy - Overview
    • Birch Pollen Allergy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Birch Pollen Allergy - Therapeutics Assessment
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Birch Pollen Allergy - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Allergy Therapeutics Plc
    • Anergis SA
    • Biomay AG
    • HAL Allergy BV
    • Laboratorios LETI SL
  • Birch Pollen Allergy - Drug Profiles
    • Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AllerT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BM-31 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pollinex Quattro Tree - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Birch Pollen Allergy - Dormant Projects
  • Birch Pollen Allergy - Discontinued Products
  • Birch Pollen Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Mar 16, 2017: Allergy Therapeutics Announces First Patient Recruited in Pivotal Phase III Birch Immunotherapy B301 Study
      • Feb 08, 2017: Anergis Completes Patient Recruitment In Large-Scale ATIBAR Trial With Ultra-Fast Allergy Immunotherapy AllerT
      • Jun 07, 2016: Anergis to Present New Data on Lead Compound AllerT at the 35th European Academy of Allergy and Clinical Immunology Congress 2016
      • May 17, 2016: HAL Allergy has successfully completed its Phase III short-term efficacy trial with its sublingual allergen immunotherapy (SLIT) liquid product for the treatment of birch pollen allergy
      • May 09, 2016: Allergy Therapeutics Announces Positive Top-Line Results From the PQBirch204 Phase II Study for Birch-Induced Seasonal Allergic Rhinitis
      • Sep 01, 2015: First patient recruited in Pollinex Quattro Birch dose ranging study in Germany and Austria
      • Jun 04, 2015: Anergis to Present Three Scientific Posters at 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015
      • Apr 01, 2015: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial
      • Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen
      • Feb 23, 2015: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting
      • Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT
      • Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT
      • May 27, 2014: Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen
      • Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT
      • Feb 27, 2014: Phase IIb Results of Anergis´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Birch Pollen Allergy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Birch Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2017
  • Birch Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H2 2017
  • Birch Pollen Allergy - Pipeline by Anergis SA, H2 2017
  • Birch Pollen Allergy - Pipeline by Biomay AG, H2 2017
  • Birch Pollen Allergy - Pipeline by HAL Allergy BV, H2 2017
  • Birch Pollen Allergy - Pipeline by Laboratorios LETI SL, H2 2017
  • Birch Pollen Allergy - Dormant Projects, H2 2017
  • Birch Pollen Allergy - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Birch Pollen Allergy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top